{"gene":"CD99","run_date":"2026-04-28T17:28:52","timeline":{"discoveries":[{"year":1989,"finding":"CD99 (E2/MIC2 gene product) is a 32 kDa transmembrane glycoprotein involved in spontaneous rosette formation (homotypic adhesion) of T cells with erythrocytes, establishing its role in T cell adhesion processes.","method":"cDNA cloning, mAb blocking of rosette formation, Northern blotting","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 — original molecular identification with functional antibody blocking, replicated by multiple subsequent studies","pmids":["2479542"],"is_preprint":false},{"year":1995,"finding":"CD99 (E2) engagement by specific mAbs triggers homotypic aggregation exclusively of CD4+CD8+ double-positive thymocytes through a pathway dependent on temperature, energy, Mg2+, and intact cytoskeleton, likely mediated by an uncharacterized integrin.","method":"mAb crosslinking, cell aggregation assay, integrin blocking experiments, live cell imaging","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — clean loss-of-function (blocking antibodies) with specific cellular phenotype, mechanistic follow-up with integrin panels","pmids":["7527813"],"is_preprint":false},{"year":1997,"finding":"CD99 engagement mediates apoptosis of immature double-positive (CD4+CD8+) thymocytes through a caspase-dependent (CPP32/ICE-type protease) pathway involving early mitochondrial alterations and phosphatidylserine exposure, without DNA fragmentation, independent of the Fas/CD95 pathway.","method":"mAb-mediated ligation, morphologic analysis, phosphatidylserine exposure assay, caspase inhibitor studies, Fas pathway blockade","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods, specific inhibitor controls, clear mechanistic separation from Fas pathway","pmids":["9058785"],"is_preprint":false},{"year":1998,"finding":"CD99 engagement on immature thymocytes accelerates mobilization of TCR and MHC class I/II molecules from cytosolic compartments to the plasma membrane (particularly at cell-cell contact sites), without increasing RNA or protein synthesis, suggesting a role in positive selection.","method":"mAb ligation, flow cytometry, confocal microscopy, subcellular fractionation","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — direct localization experiment tied to functional consequence, multiple methods","pmids":["9670951"],"is_preprint":false},{"year":1998,"finding":"Downregulation of CD99 leads to generation of cells with Hodgkin's/Reed-Sternberg (H-RS) phenotype (multinuclearity, CD15 expression, decreased MHC class I and CD45RB, deregulated cytokine secretion), and forced CD99 expression or constitutively active Rac rescues this phenotype, placing CD99 upstream of a Rac-Rho signaling pathway.","method":"Antisense transfection, forced expression, constitutively active Rac expression, immunophenotyping","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis via rescue experiment with constitutively active Rac, replicated in patient samples","pmids":["9834235"],"is_preprint":false},{"year":1999,"finding":"CD99 crosslinking with anti-CD3 Ab markedly enhances T cell proliferation and induces tyrosine phosphorylation of an ~29 kDa protein, demonstrating that CD99 can deliver costimulatory signals via a specific signal transduction pathway in CD4+ peripheral T cells.","method":"mAb crosslinking, proliferation assay, tyrosine phosphorylation immunoblot, CD25/CD69/CD40L expression","journal":"Cellular immunology","confidence":"Medium","confidence_rationale":"Tier 3 — single lab, consistent functional readout but downstream pathway not fully resolved","pmids":["10202109"],"is_preprint":false},{"year":2000,"finding":"CD99 stimulation upregulates alpha4beta1 integrin-dependent T cell arrest on inflamed vascular endothelium under shear stress via the alpha4beta1-VCAM-1 pathway (not alphaLbeta2-ICAM-1), restricted to memory CD4+ T cells.","method":"Flow adhesion assay under shear stress, integrin blocking antibodies, T cell subset analysis","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — specific pathway dissection with integrin blocking, physiological flow conditions","pmids":["11069091"],"is_preprint":false},{"year":2000,"finding":"EBV latent membrane protein 1 (LMP-1) downregulates CD99 expression at the transcriptional level by negatively regulating the CD99 promoter, contributing to H-RS cell generation in Hodgkin's disease.","method":"Stable transfection of LMP-1, CD99 promoter-luciferase reporter assay, Northern/Western blotting","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 — promoter reporter assay plus stable transfection with multiple readouts, mechanistically defined","pmids":["10607715"],"is_preprint":false},{"year":2001,"finding":"Engagement of specific CD99 epitopes rapidly induces caspase-independent programmed cell death in transformed T cells (but not normal peripheral T cells), distinct from Fas and TRAIL pathways and independent of CD3, CD4, CD45, and p56lck.","method":"mAb ligation, morphological analysis, phosphatidylserine exposure, propidium iodide uptake, pathway inhibition experiments","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — rigorous exclusion of known death pathways with multiple controls, replicated across T cell lines","pmids":["11290771"],"is_preprint":false},{"year":2002,"finding":"The two CD99 isoforms (long form and short form) have distinct functional outcomes: the long form alone promotes CD99-induced cell adhesion, whereas coexpression of both isoforms is required to trigger T cell death. When coexpressed, the two proteins form covalent heterodimers located within glycosphingolipid rafts, and raft localization (cholesterol-dependent) is required for apoptosis induction, which involves sphingomyelin degradation.","method":"Isoform transfection in CD99-deficient Jurkat cells, lipid raft fractionation, cholesterol depletion, sphingomyelin assay, cell death assays","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 1–2 — reconstitution in deficient cells with mechanistic follow-up (raft localization, lipid signaling), multiple orthogonal methods","pmids":["12368226"],"is_preprint":false},{"year":2003,"finding":"CD99 ligation via the YG32 epitope enhances Fas-mediated apoptosis in Jurkat T cells by inducing Fas oligomerization, in a caspase-8-dependent manner (blocked by z-IETD-fmk).","method":"Epitope-specific mAb ligation, Fas oligomerization assay, caspase inhibitor studies","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 — specific mechanistic finding (Fas oligomerization) with inhibitor confirmation, single lab","pmids":["14623115"],"is_preprint":false},{"year":2004,"finding":"Mouse CD99 mediates homophilic cell aggregation (divalent cation-dependent) when transfected into CHO cells; anti-CD99 antibodies block transendothelial migration (TEM) of lymphocytes in vitro independent of which cell type (T cell or endothelial) is pre-treated, and inhibit recruitment of T cells to inflamed skin in a DTH model in vivo.","method":"CHO transfection/aggregation assay, in vitro TEM assay, in vivo DTH model with antibody blockade","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — in vitro and in vivo validation with mechanistic dissection of which cell type requires CD99","pmids":["15280198"],"is_preprint":false},{"year":2006,"finding":"CD99 knockdown in Ewing sarcoma cells reduces growth and migration; CD99 suppresses KCMF1 (potassium-channel modulatory factor 1) expression, and forced KCMF1 expression recapitulates reduced migration, identifying KCMF1 as a downstream mediator through which CD99 promotes cell migration in EWS.","method":"RNAi knockdown, rescue with ectopic KCMF1 expression, migration assays, gene expression analysis","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — epistasis via rescue experiment, multiple EWS cell lines tested","pmids":["16314831"],"is_preprint":false},{"year":2008,"finding":"CD99 regulates HLA class I surface expression by physically associating with HLA class I molecules (via transmembrane domain) in the trans-Golgi network and binding p230/golgin-245 (a TGN trafficking protein); IFN-gamma-induced HLA class I upregulation requires CD99, and p230/golgin-245 overexpression downmodulates surface HLA class I.","method":"Co-immunoprecipitation, confocal microscopy, TGN fractionation, p230 overexpression, IFN-gamma stimulation","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — reciprocal co-IP, subcellular fractionation, functional consequence of interaction established","pmids":["18849489"],"is_preprint":false},{"year":2008,"finding":"CD99 is recognized as a sialylated O-glycoprotein ligand for paired Ig-like type 2 receptors (PILRs); PILRalpha binds CD99 with Kd ~2.2 µM and PILRbeta with ~85 µM affinity; both O-glycosylation sites (Thr-45 and Thr-50) act as independent PILRalpha binding sites, while PILRbeta specifically requires Thr-45; binding is enthalpically driven for PILRalpha.","method":"Surface plasmon resonance, site-directed mutagenesis, thermodynamic analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with SPR kinetics and mutagenesis, quantitative biophysical characterization","pmids":["18234675"],"is_preprint":false},{"year":2010,"finding":"CD99 knockdown in Ewing sarcoma cells reduces tumorigenicity and bone metastasis, induces neurite outgrowth and neural differentiation markers (beta-III tubulin), and increases ERK1/2 phosphorylation, placing CD99 as an inhibitor of neural differentiation acting through the MAPK pathway.","method":"shRNA knockdown, xenograft model, neurite outgrowth assay, ERK1/2 phosphorylation immunoblot, differentiation marker expression","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — in vitro and in vivo KD with mechanistic pathway (MAPK/ERK) identification, multiple differentiation readouts","pmids":["20197622"],"is_preprint":false},{"year":2013,"finding":"CD99 suppresses osteosarcoma cell migration by: forcing expression of CD99wt recruits N-cadherin and β-catenin to adherens junctions; inhibits ACTR2, ARPC1A, ROCK2, and ezrin expression; maintains c-Src in an inactive conformation, thereby inhibiting ROCK2 signaling and reducing ezrin at the cell membrane.","method":"Forced expression, migration assays, co-immunoprecipitation, immunoblotting, actin cytoskeleton analysis","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods, specific molecular pathway (c-Src/ROCK2/ezrin axis) defined","pmids":["23644663"],"is_preprint":false},{"year":2013,"finding":"Overexpression of CD99 in glioma cells enhances migration and invasion; CD99 overexpression decreases Rac activity and increases Rho activity, promoting amoeboid cell morphology, independently of Akt, ERK, or JNK signaling.","method":"siRNA knockdown, overexpression, orthotopic mouse model, Rac/Rho activity assays, invasion assays","journal":"Genes & cancer","confidence":"High","confidence_rationale":"Tier 2 — loss-of-function and gain-of-function with defined pathway (Rac/Rho) and in vivo validation","pmids":["23486730"],"is_preprint":false},{"year":2013,"finding":"miR-30a-5p binds the 3'UTR of CD99 and regulates its protein expression post-transcriptionally; EWS-FLI1 suppression decreases CD99 protein but not mRNA, mediated through miR-30a-5p induction; re-expression of miR-30a-5p in Ewing cells decreases proliferation and invasion.","method":"miRNA 3'UTR reporter assay, miRNA overexpression, protein/mRNA quantification, proliferation and invasion assays","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — direct 3'UTR binding demonstrated, mechanistic link between EWS-FLI1/miR-30a-5p/CD99 established","pmids":["22986530"],"is_preprint":false},{"year":2014,"finding":"Anti-CD99 antibody (dAbd C7) triggers Ewing sarcoma cell death through Mdm2 degradation and p53 reactivation, with induction of p21, Bax, and mitochondrial depolarization; Mdm2 overexpression or p53 silencing reduces CD99-induced death, while nutlin-3 enhances it, requiring an aberrant (EWS-FLI1) genetic context.","method":"Anti-CD99 diabody treatment, Mdm2 overexpression, p53 siRNA, nutlin-3 treatment, in vivo xenograft","journal":"Clinical cancer research","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis (Mdm2/p53) with rescue/knockdown, in vitro and in vivo","pmids":["25501132"],"is_preprint":false},{"year":2015,"finding":"Endothelial CD99 signals during transendothelial migration (TEM) by forming a complex with the A-kinase anchoring protein ezrin and soluble adenylyl cyclase (sAC) via its lysine-rich juxtamembrane cytoplasmic tail; this activates PKA, which stimulates membrane trafficking from the lateral border recycling compartment (LBRC) to facilitate leukocyte passage; pharmacologic or genetic inhibition of sAC or PKA arrests neutrophils and monocytes partway through endothelial junctions in vitro and in vivo.","method":"Co-immunoprecipitation (CD99-ezrin-sAC complex), sAC pharmacologic inhibition, PKA inhibition, genetic knockdown, in vivo inflammation model, LBRC trafficking assay","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1–2 — complex identified by co-IP, mechanistic pathway (sAC-PKA-LBRC) validated by pharmacologic and genetic inhibition in vitro and in vivo","pmids":["26101266"],"is_preprint":false},{"year":2016,"finding":"Ectodomain shedding of CD99 is mediated by the metalloprotease meprin β (with cleavage at an acidic region conserved across vertebrates, consistent with meprin β's preference for aspartate residues), followed by intramembrane proteolysis by γ-secretase; meprin β-induced CD99 shedding promotes transendothelial cell migration, and Mep1b-/- mice have significantly increased CD99 protein levels in lung.","method":"Biochemical shedding assay, mass spectrometry cleavage site identification, meprin β-/- mouse model, in vitro TEM assay, γ-secretase inhibitor","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 1–2 — cleavage site identified by MS, genetic KO mouse validation, functional consequence in TEM demonstrated","pmids":["28003343"],"is_preprint":false},{"year":2017,"finding":"Endothelial CD99 (not leukocyte CD99) supports rapid chemokine-induced neutrophil arrest on venular endothelium and acts at the diapedesis step; endothelial CD99 binds heterophilically to paired immunoglobulin-like receptors (PILRs) on neutrophils, promoting shear-resistant attachment; this interaction was confirmed by co-precipitation and biotin-transfer assays.","method":"CD99 gene inactivation in mice, intravital video microscopy, co-precipitation, biotin-transfer assay, flow adhesion assay with anti-PILR antibodies","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 — KO mouse, intravital microscopy, biochemical interaction confirmation, multiple orthogonal methods","pmids":["28223280"],"is_preprint":false},{"year":2018,"finding":"Anti-CD99 monoclonal antibodies activate hyperstimulation of macropinocytosis in Ewing sarcoma cells leading to caspase-independent, non-apoptotic cell death resembling methuosis (cytoplasmic vacuole accumulation), requiring RAS-Rac1 downstream signaling; this effect is specific to tumor cells and active in xenografts without immune effectors or complement.","method":"Anti-CD99 mAb treatment, macropinocytosis assay, vacuole quantification, RAS-Rac1 pathway inhibition, xenograft model","journal":"Journal of cell communication and signaling","confidence":"Medium","confidence_rationale":"Tier 2 — defined mechanism (macropinocytosis/RAS-Rac1) with in vivo validation, review synthesis of prior experimental work","pmids":["29305692"],"is_preprint":false},{"year":2018,"finding":"Clofarabine directly binds the extracellular domain of CD99, inhibits CD99 dimerization and its interaction with downstream signaling components; a membrane-impermeable clofarabine analog retains cytotoxicity, indicating a CD99-surface mechanism independent of intracellular DNA metabolism.","method":"Small molecule library screen for CD99 binding, CD99 dimerization assay, membrane-impermeable analog, xenograft model","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — direct binding screen, dimerization assay, membrane-impermeable analog as mechanistic control; single lab","pmids":["29382926"],"is_preprint":false},{"year":2019,"finding":"CD99 long isoform transiently induces ERK and SRC phosphorylation followed by a dramatic decrease; it also induces reactive oxygen species, DNA damage, and apoptosis in AML cells, delaying disease progression in murine leukemia models.","method":"Isoform-specific transfection, ERK/SRC phosphorylation immunoblot, ROS assay, DNA damage assay, murine leukemia model","journal":"Haematologica","confidence":"Medium","confidence_rationale":"Tier 2 — isoform-specific effects with defined signaling pathway, in vitro and in vivo; single lab","pmids":["31371417"],"is_preprint":false},{"year":2019,"finding":"Nrf2 transcriptionally activates CD99 expression (demonstrated by dual-luciferase reporter assay and ChIP), and this CD99 upregulation mediates Nrf2-induced cisplatin resistance in ovarian cancer cells; CD99 knockdown reverses Nrf2-driven resistance.","method":"Dual-luciferase reporter assay, ChIP, Nrf2 and CD99 knockdown/overexpression, CCK-8 viability assay","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — promoter binding confirmed by ChIP and reporter assay, genetic epistasis demonstrated; single lab","pmids":["31472965"],"is_preprint":false},{"year":2020,"finding":"The GDF6 prodomain (not the BMP domain) is a ligand for the CD99 extracellular domain; binding recruits CSK (C-terminal Src kinase) to the YQKKK motif in the CD99 intracellular domain, inhibiting Src activity and maintaining Ewing sarcoma cell proliferation; GDF6 silencing causes Src hyperactivation and p21-dependent growth arrest.","method":"Co-immunoprecipitation (GDF6 prodomain-CD99), domain mapping, CSK recruitment assay, Src activity assay, GDF6 silencing, p21 reporter","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — co-IP identifying ligand-receptor interaction, specific intracellular docking motif (YQKKK) identified, downstream kinase (CSK-Src) mechanism defined","pmids":["33147457"],"is_preprint":false},{"year":2011,"finding":"CD99 upregulation in Hodgkin/Reed-Sternberg cells induces PRDM1/BLIMP1 expression by suppressing miR-9, which directly targets PRDM1; this CD99-miR-9-PRDM1 axis promotes terminal B-cell differentiation and reorganization of actin cytoskeleton in H/RS cells.","method":"CD99 overexpression, miR-9 inhibition, PRDM1 reporter, actin cytoskeleton staining, CD30/CD15/CD38/PAX5 expression analysis","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 — miR-9 as downstream mediator validated by inhibition experiments, multiple differentiation markers assessed; single lab","pmids":["22020966"],"is_preprint":false},{"year":2021,"finding":"Mosaic loss of chromosome Y (LOY) in leukocytes reduces CD99 protein abundance on the cell surface (across all six leukocyte types studied), directly linking Y chromosome copy number to CD99 surface expression at the single-cell level.","method":"CITE-seq (simultaneous single-cell mRNA and protein quantification), comparison of LOY vs. non-LOY cells","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 — single-cell multi-omic quantification, specific to CD99 (autosomal CD proteins unaffected), replicated across six leukocyte types","pmids":["34312421"],"is_preprint":false}],"current_model":"CD99 (MIC2 gene product) is a heavily O-glycosylated transmembrane glycoprotein with two isoforms (long/short) that acts as a multifunctional signaling hub: it mediates homotypic T cell adhesion via alpha4beta1 integrin activation, promotes leukocyte transendothelial migration by forming a complex with ezrin and soluble adenylyl cyclase to activate PKA and drive LBRC trafficking, undergoes ectodomain shedding by meprin β and intramembrane cleavage by γ-secretase, interacts heterophilically with neutrophil PILRs via O-glycosylated Thr-45/Thr-50 residues, recruits CSK to its cytoplasmic YQKKK motif upon GDF6 prodomain binding to inhibit Src, signals apoptosis through lipid raft-localized covalent heterodimers activating sphingomyelinase, suppresses osteosarcoma migration via c-Src/ROCK2/ezrin inhibition and N-cadherin/β-catenin stabilization, and in Ewing sarcoma prevents neural differentiation through MAPK/ERK modulation while its downregulation is driven by EBV LMP-1 transcriptionally and post-transcriptionally by miR-30a-5p."},"narrative":{"teleology":[{"year":1989,"claim":"Identification of CD99 as the molecular basis of T cell rosette formation established it as a transmembrane glycoprotein with a direct role in homotypic adhesion, answering the long-standing question of the MIC2 gene product's function.","evidence":"cDNA cloning plus mAb blocking of rosette formation in human T cells","pmids":["2479542"],"confidence":"High","gaps":["Mechanism of homotypic adhesion (homophilic vs. heterophilic) not resolved","No signaling pathway identified downstream of engagement"]},{"year":1997,"claim":"The discovery that CD99 ligation induces caspase-dependent apoptosis of CD4+CD8+ thymocytes independent of Fas/CD95 revealed CD99 as a death-signaling receptor on immature T cells, reframing it from a pure adhesion molecule to a regulator of thymic selection.","evidence":"mAb ligation on thymocytes with caspase inhibitors and Fas pathway blockade","pmids":["9058785"],"confidence":"High","gaps":["Proximal signaling intermediates between CD99 and caspase activation unknown","In vivo relevance in thymic selection not demonstrated"]},{"year":1998,"claim":"Two key advances defined CD99's roles beyond adhesion: it accelerates TCR/MHC transport to the surface of thymocytes (implicating it in positive selection), and its loss generates Hodgkin/Reed-Sternberg phenotype rescued by constitutively active Rac, placing CD99 upstream of Rac-Rho signaling.","evidence":"Confocal microscopy/subcellular fractionation for TCR transport; antisense knockdown with Rac rescue for H-RS phenotype","pmids":["9670951","9834235"],"confidence":"High","gaps":["Direct physical link between CD99 and Rac-GTPase activation not shown","Mechanism of TCR/MHC vesicle mobilization undefined"]},{"year":2000,"claim":"Demonstrating that CD99 engagement activates α4β1 integrin–dependent arrest under shear stress on memory CD4+ T cells, and that EBV LMP-1 transcriptionally represses CD99, connected CD99 to physiological leukocyte trafficking and to Hodgkin lymphoma pathogenesis.","evidence":"Flow adhesion assay with integrin blocking; LMP-1 stable transfection with CD99 promoter-luciferase reporter","pmids":["11069091","10607715"],"confidence":"High","gaps":["Signaling intermediates between CD99 and α4β1 activation not identified","LMP-1 cis-elements on CD99 promoter not mapped"]},{"year":2002,"claim":"The finding that apoptosis requires coexpression of both CD99 isoforms as covalent heterodimers in lipid rafts activating sphingomyelinase resolved how a single gene generates distinct adhesion versus death outcomes through isoform-specific oligomerization and membrane microdomain partitioning.","evidence":"Isoform reconstitution in CD99-deficient Jurkat cells, lipid raft fractionation, cholesterol depletion, sphingomyelin assay","pmids":["12368226"],"confidence":"High","gaps":["Identity of the sphingomyelinase activated is unknown","Structural basis for covalent heterodimer formation undefined"]},{"year":2004,"claim":"Blocking experiments in vitro and in vivo showed that CD99 on both leukocytes and endothelium mediates homophilic interaction required for transendothelial migration, establishing CD99 as a gatekeeper of diapedesis distinct from PECAM-1.","evidence":"CHO transfection/aggregation, in vitro TEM assay, DTH model with anti-CD99 antibody in mice","pmids":["15280198"],"confidence":"High","gaps":["Whether CD99 acts sequentially with or independently of PECAM-1 during TEM not fully resolved","Endothelial signaling downstream of homophilic engagement unknown at this point"]},{"year":2008,"claim":"Two studies in 2008 defined new molecular partnerships: CD99 associates with HLA class I via its transmembrane domain and p230/golgin-245 in the TGN to regulate MHC I surface transport, and CD99 serves as a sialylated O-glycoprotein ligand for PILRα/β with defined binding affinities and glycosylation-site specificity.","evidence":"Reciprocal co-IP and TGN fractionation for HLA/p230; SPR with site-directed mutagenesis for PILR binding","pmids":["18849489","18234675"],"confidence":"High","gaps":["Functional consequence of PILR binding on neutrophil physiology not yet shown","Whether HLA I trafficking role applies beyond lymphocytes not tested"]},{"year":2010,"claim":"CD99 knockdown in Ewing sarcoma induced neural differentiation with increased ERK1/2 phosphorylation and reduced tumorigenicity, establishing CD99 as an oncogene-dependent differentiation brake acting through MAPK suppression in EWS.","evidence":"shRNA knockdown in EWS cells, xenograft model, neurite outgrowth, ERK1/2 phosphorylation assay","pmids":["20197622"],"confidence":"High","gaps":["Mechanism by which CD99 suppresses ERK signaling not defined","Whether differentiation effect is cell-autonomous or microenvironment-dependent unclear"]},{"year":2013,"claim":"Three parallel studies expanded CD99's context-dependent signaling: in osteosarcoma it suppresses migration via c-Src/ROCK2/ezrin inactivation and N-cadherin stabilization; in glioma it promotes invasion via Rho activation; and in Ewing sarcoma miR-30a-5p post-transcriptionally silences CD99 downstream of EWS-FLI1 suppression.","evidence":"Forced expression in osteosarcoma with co-IP and actin analysis; overexpression/siRNA in glioma with Rac/Rho assays and orthotopic model; miR-30a-5p 3'UTR reporter assay in EWS","pmids":["23644663","23486730","22986530"],"confidence":"High","gaps":["Opposing migratory effects in osteosarcoma vs. glioma/EWS not mechanistically reconciled","miR-30a-5p regulation of CD99 not validated in non-Ewing contexts"]},{"year":2015,"claim":"The identification of endothelial CD99's signaling complex—ezrin/sAC/PKA activating LBRC trafficking—provided the first complete signaling pathway explaining how CD99 homophilic engagement mechanistically drives leukocyte diapedesis.","evidence":"Co-IP of CD99-ezrin-sAC, pharmacologic and genetic inhibition of sAC/PKA, LBRC trafficking assay, in vivo peritonitis model","pmids":["26101266"],"confidence":"High","gaps":["Whether the same sAC/PKA pathway operates in leukocyte CD99 signaling unknown","Structural basis for ezrin recruitment to CD99 cytoplasmic tail not resolved"]},{"year":2016,"claim":"Discovery that meprin β cleaves CD99's ectodomain at a conserved acidic motif followed by γ-secretase intramembrane proteolysis revealed a regulated proteolytic cascade that controls CD99 surface levels and promotes transendothelial migration.","evidence":"Biochemical shedding assay, MS cleavage site mapping, Mep1b−/− mice, γ-secretase inhibitor, TEM assay","pmids":["28003343"],"confidence":"High","gaps":["Fate and function of the released intracellular domain after γ-secretase cleavage unknown","Physiological stimuli that activate meprin β–mediated CD99 shedding not identified"]},{"year":2017,"claim":"In vivo gene inactivation and intravital microscopy demonstrated that endothelial CD99 engages neutrophil PILRs heterophilically to support chemokine-induced arrest and diapedesis, unifying the earlier biophysical PILR-binding data with a physiological leukocyte trafficking function.","evidence":"CD99 KO mice, intravital video microscopy, co-precipitation and biotin-transfer assay, anti-PILR blocking","pmids":["28223280"],"confidence":"High","gaps":["Relative contributions of homophilic CD99-CD99 vs. heterophilic CD99-PILR interactions during TEM not quantified","Whether PILR engagement triggers specific signaling in neutrophils unknown"]},{"year":2020,"claim":"Identification of the GDF6 prodomain as a CD99 extracellular ligand that recruits CSK to the intracellular YQKKK motif to inhibit Src answered how CD99 restrains growth arrest in Ewing sarcoma and provided the first defined receptor-ligand-effector signaling axis for CD99.","evidence":"Co-IP of GDF6 prodomain with CD99, domain mapping, CSK recruitment and Src activity assays, GDF6 silencing with p21 readout","pmids":["33147457"],"confidence":"High","gaps":["Whether GDF6 prodomain-CD99 interaction occurs in non-Ewing tissues unknown","Crystal structure of CD99-GDF6 prodomain complex not available","Whether CSK recruitment to YQKKK motif is direct or scaffold-mediated not resolved"]},{"year":null,"claim":"Major unresolved questions include the structural basis of CD99 homo- and hetero-oligomerization, how opposing pro-migratory (EWS, glioma) versus anti-migratory (osteosarcoma) effects are contextually determined, and whether the meprin β–released intracellular domain has signaling activity.","evidence":"","pmids":[],"confidence":"Low","gaps":["No crystal or cryo-EM structure of CD99 extracellular domain","No unified model reconciling tissue-specific opposing migratory outcomes","Intracellular domain fragment function after γ-secretase cleavage uncharacterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[0,1,11]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[2,9,20,27]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[4,16,17,27]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,3,9,14,22,29]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[13]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[1,6,11,20,21,22]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[2,8,9,19]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[4,5,15,16,17,27]},{"term_id":"R-HSA-1500931","term_label":"Cell-Cell communication","supporting_discovery_ids":[0,6,11,20]}],"complexes":["CD99-ezrin-sAC signaling complex","CD99 long/short isoform heterodimer"],"partners":["ITGA4","EZR","ADCY10","PILRA","PILRB","MEP1B","GDF6","CSK"],"other_free_text":[]},"mechanistic_narrative":"CD99 is a heavily O-glycosylated type I transmembrane glycoprotein that functions as a multifaceted regulator of cell adhesion, transendothelial migration, apoptosis, and differentiation across hematopoietic and mesenchymal lineages. In immune cells, CD99 engagement activates α4β1 integrin–dependent T cell adhesion, promotes leukocyte diapedesis through an endothelial ezrin–soluble adenylyl cyclase–PKA signaling axis that drives lateral border recycling compartment trafficking, and interacts heterophilically with neutrophil PILRs via O-glycosylated Thr-45/Thr-50 residues; its ectodomain is shed by meprin β followed by γ-secretase intramembrane cleavage [PMID:11069091, PMID:26101266, PMID:28223280, PMID:18234675, PMID:28003343]. CD99 signals apoptosis in thymocytes and transformed T cells through covalent long/short isoform heterodimers localized in lipid rafts that activate sphingomyelinase, and in Ewing sarcoma the GDF6 prodomain binds CD99's ectodomain to recruit CSK to its cytoplasmic YQKKK motif, inhibiting Src and maintaining proliferation, while CD99 silencing derepresses MAPK/ERK signaling and triggers neural differentiation [PMID:12368226, PMID:33147457, PMID:20197622]. Loss of CD99 expression—driven transcriptionally by EBV LMP-1 or post-transcriptionally by miR-30a-5p—generates Hodgkin/Reed-Sternberg cell features and deregulates Rac-Rho signaling, whereas in osteosarcoma CD99 suppresses migration by inactivating c-Src/ROCK2/ezrin and stabilizing N-cadherin/β-catenin at adherens junctions [PMID:10607715, PMID:22986530, PMID:9834235, PMID:23644663]."},"prefetch_data":{"uniprot":{"accession":"P14209","full_name":"CD99 antigen","aliases":["12E7","E2 antigen","Protein MIC2","T-cell surface glycoprotein E2"],"length_aa":185,"mass_kda":18.8,"function":"Involved in T-cell adhesion processes and in spontaneous rosette formation with erythrocytes. Plays a role in a late step of leukocyte extravasation helping leukocytes to overcome the endothelial basement membrane. Acts at the same site as, but independently of, PECAM1. Involved in T-cell adhesion processes (By similarity)","subcellular_location":"Membrane","url":"https://www.uniprot.org/uniprotkb/P14209/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CD99","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":74,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"SLC16A1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/CD99","total_profiled":1310},"omim":[{"mim_id":"616065","title":"PILR-ALPHA-ASSOCIATED NEURAL PROTEIN; PIANP","url":"https://www.omim.org/entry/616065"},{"mim_id":"612219","title":"EWING SARCOMA; ES","url":"https://www.omim.org/entry/612219"},{"mim_id":"605342","title":"PAIRED IMMUNOGLOBULIN-LIKE TYPE 2 RECEPTOR, BETA; PILRB","url":"https://www.omim.org/entry/605342"},{"mim_id":"605341","title":"PAIRED IMMUNOGLOBULIN-LIKE TYPE 2 RECEPTOR, ALPHA; PILRA","url":"https://www.omim.org/entry/605341"},{"mim_id":"600711","title":"ETS VARIANT TRANSCRIPTION FACTOR 4; ETV4","url":"https://www.omim.org/entry/600711"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Golgi apparatus","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CD99"},"hgnc":{"alias_symbol":[],"prev_symbol":["MIC2","MIC2X","MIC2Y"]},"alphafold":{"accession":"P14209","domains":[{"cath_id":"-","chopping":"2-151","consensus_level":"medium","plddt":62.9992,"start":2,"end":151}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P14209","model_url":"https://alphafold.ebi.ac.uk/files/AF-P14209-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P14209-F1-predicted_aligned_error_v6.png","plddt_mean":60.84},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CD99","jax_strain_url":"https://www.jax.org/strain/search?query=CD99"},"sequence":{"accession":"P14209","fasta_url":"https://rest.uniprot.org/uniprotkb/P14209.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P14209/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P14209"}},"corpus_meta":[{"pmid":"12727875","id":"PMC_12727875","title":"Rapid invasion of host cells by Toxoplasma requires secretion of the MIC2-M2AP adhesive protein complex.","date":"2003","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/12727875","citation_count":204,"is_preprint":false},{"pmid":"16933991","id":"PMC_16933991","title":"Toxoplasma MIC2 is a major determinant of invasion and virulence.","date":"2006","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/16933991","citation_count":169,"is_preprint":false},{"pmid":"1695726","id":"PMC_1695726","title":"Overexpression of the pseudoautosomal gene MIC2 in Ewing's sarcoma and peripheral primitive neuroectodermal tumor.","date":"1990","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/1695726","citation_count":166,"is_preprint":false},{"pmid":"10799515","id":"PMC_10799515","title":"The Toxoplasma adhesive protein MIC2 is proteolytically processed at multiple sites by two parasite-derived proteases.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10799515","citation_count":155,"is_preprint":false},{"pmid":"2479542","id":"PMC_2479542","title":"The E2 antigen, a 32 kd glycoprotein involved in T-cell adhesion processes, is the MIC2 gene product.","date":"1989","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/2479542","citation_count":153,"is_preprint":false},{"pmid":"9084040","id":"PMC_9084040","title":"Molecular characterisation of an expressed sequence tag locus of Toxoplasma gondii encoding the micronemal protein MIC2.","date":"1997","source":"Molecular and biochemical parasitology","url":"https://pubmed.ncbi.nlm.nih.gov/9084040","citation_count":152,"is_preprint":false},{"pmid":"20197622","id":"PMC_20197622","title":"CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis.","date":"2010","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/20197622","citation_count":134,"is_preprint":false},{"pmid":"9058785","id":"PMC_9058785","title":"Apoptosis of immature thymocytes mediated by E2/CD99.","date":"1997","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9058785","citation_count":124,"is_preprint":false},{"pmid":"8150461","id":"PMC_8150461","title":"Ewing's sarcoma--routine diagnostic utilization of MIC2 analysis: a Pediatric Oncology Group/Children's Cancer Group Intergroup Study.","date":"1994","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/8150461","citation_count":122,"is_preprint":false},{"pmid":"29305692","id":"PMC_29305692","title":"CD99 at the crossroads of physiology and pathology.","date":"2018","source":"Journal of cell communication and signaling","url":"https://pubmed.ncbi.nlm.nih.gov/29305692","citation_count":117,"is_preprint":false},{"pmid":"6540985","id":"PMC_6540985","title":"The cell surface antigen locus, MIC2X, escapes X-inactivation.","date":"1984","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/6540985","citation_count":114,"is_preprint":false},{"pmid":"14970179","id":"PMC_14970179","title":"Activation of natural killer cells and dendritic cells upon recognition of a novel CD99-like ligand by paired immunoglobulin-like type 2 receptor.","date":"2004","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/14970179","citation_count":114,"is_preprint":false},{"pmid":"15280198","id":"PMC_15280198","title":"Mouse CD99 participates in T-cell recruitment into inflamed skin.","date":"2004","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15280198","citation_count":109,"is_preprint":false},{"pmid":"7506950","id":"PMC_7506950","title":"Flow cytometric assessment of human MIC2 expression in bone marrow, thymus, and peripheral blood.","date":"1994","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/7506950","citation_count":108,"is_preprint":false},{"pmid":"18346224","id":"PMC_18346224","title":"The Plasmodium TRAP/MIC2 family member, TRAP-Like Protein (TLP), is involved in tissue traversal by sporozoites.","date":"2008","source":"Cellular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/18346224","citation_count":94,"is_preprint":false},{"pmid":"7527813","id":"PMC_7527813","title":"The E2 molecule (CD99) specifically triggers homotypic aggregation of CD4+ CD8+ thymocytes.","date":"1995","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7527813","citation_count":89,"is_preprint":false},{"pmid":"26101266","id":"PMC_26101266","title":"Endothelial CD99 signals through soluble adenylyl cyclase and PKA to regulate leukocyte transendothelial migration.","date":"2015","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26101266","citation_count":88,"is_preprint":false},{"pmid":"10374776","id":"PMC_10374776","title":"Inhibin and CD99 (MIC2) expression in uterine stromal neoplasms with sex-cord-like elements.","date":"1999","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/10374776","citation_count":88,"is_preprint":false},{"pmid":"8163272","id":"PMC_8163272","title":"MIC2 analysis in pediatric lymphomas and leukemias.","date":"1994","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/8163272","citation_count":87,"is_preprint":false},{"pmid":"11290771","id":"PMC_11290771","title":"CD99 signals caspase-independent T cell death.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11290771","citation_count":84,"is_preprint":false},{"pmid":"25031013","id":"PMC_25031013","title":"The combination of CD99 and NKX2.2, a transcriptional target of EWSR1-FLI1, is highly specific for the diagnosis of Ewing sarcoma.","date":"2014","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25031013","citation_count":84,"is_preprint":false},{"pmid":"11014571","id":"PMC_11014571","title":"Inhibin-alpha CD99, HEA125, PLAP, and chromogranin immunoreactivity in testicular neoplasms and the androgen insensitivity syndrome.","date":"2000","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11014571","citation_count":78,"is_preprint":false},{"pmid":"8054981","id":"PMC_8054981","title":"Cloning of PBDX, an MIC2-related gene that spans the pseudoautosomal boundary on chromosome Xp.","date":"1994","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8054981","citation_count":77,"is_preprint":false},{"pmid":"29534016","id":"PMC_29534016","title":"CD99: A Cell Surface Protein with an Oncojanus Role in Tumors.","date":"2018","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/29534016","citation_count":72,"is_preprint":false},{"pmid":"25957287","id":"PMC_25957287","title":"A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia.","date":"2015","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/25957287","citation_count":71,"is_preprint":false},{"pmid":"22986530","id":"PMC_22986530","title":"MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/22986530","citation_count":70,"is_preprint":false},{"pmid":"12471033","id":"PMC_12471033","title":"C-terminal processing of the toxoplasma protein MIC2 is essential for invasion into host cells.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12471033","citation_count":69,"is_preprint":false},{"pmid":"9720506","id":"PMC_9720506","title":"CD99, keratin, and vimentin staining of sex cord-stromal tumors, normal ovary, and testis.","date":"1998","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/9720506","citation_count":65,"is_preprint":false},{"pmid":"11069091","id":"PMC_11069091","title":"CD99 (E2) up-regulates alpha4beta1-dependent T cell adhesion to inflamed vascular endothelium under flow conditions.","date":"2000","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11069091","citation_count":63,"is_preprint":false},{"pmid":"12368226","id":"PMC_12368226","title":"CD99 isoforms expression dictates T cell functional outcomes.","date":"2002","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/12368226","citation_count":62,"is_preprint":false},{"pmid":"10607715","id":"PMC_10607715","title":"Viral latent membrane protein 1 (LMP-1)-induced CD99 down-regulation in B cells leads to the generation of cells with Hodgkin's and Reed-Sternberg phenotype.","date":"2000","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/10607715","citation_count":61,"is_preprint":false},{"pmid":"26722515","id":"PMC_26722515","title":"Immunohistochemical detection of STAT6, CD34, CD99 and BCL-2 for diagnosing solitary fibrous tumors/hemangiopericytomas.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26722515","citation_count":59,"is_preprint":false},{"pmid":"23333754","id":"PMC_23333754","title":"Poliovirus receptor (CD155) regulates a step in transendothelial migration between PECAM and CD99.","date":"2013","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23333754","citation_count":58,"is_preprint":false},{"pmid":"9670951","id":"PMC_9670951","title":"Engagement of CD99 induces up-regulation of TCR and MHC class I and II molecules on the surface of human thymocytes.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9670951","citation_count":57,"is_preprint":false},{"pmid":"22575993","id":"PMC_22575993","title":"Sex differences in inflammatory cytokines and CD99 expression following in vitro lipopolysaccharide stimulation.","date":"2012","source":"Shock (Augusta, Ga.)","url":"https://pubmed.ncbi.nlm.nih.gov/22575993","citation_count":51,"is_preprint":false},{"pmid":"9834235","id":"PMC_9834235","title":"Generation of cells with Hodgkin's and Reed-Sternberg phenotype through downregulation of CD99 (Mic2).","date":"1998","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9834235","citation_count":50,"is_preprint":false},{"pmid":"7524308","id":"PMC_7524308","title":"MIC2 analysis of small cell carcinoma.","date":"1994","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/7524308","citation_count":50,"is_preprint":false},{"pmid":"16972949","id":"PMC_16972949","title":"CD99 immunoreactivity in atypical fibroxanthoma and pleomorphic malignant fibrous histiocytoma: a useful diagnostic marker.","date":"2006","source":"Journal of cutaneous pathology","url":"https://pubmed.ncbi.nlm.nih.gov/16972949","citation_count":50,"is_preprint":false},{"pmid":"24337626","id":"PMC_24337626","title":"Neutrophil and monocyte recruitment by PECAM, CD99, and other molecules via the LBRC.","date":"2013","source":"Seminars in immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/24337626","citation_count":49,"is_preprint":false},{"pmid":"9343323","id":"PMC_9343323","title":"MIC2, TdT, bcl-2, and CD34 expression in paraffin-embedded high-grade lymphoma/acute lymphoblastic leukemia distinguishes between distinct clinicopathologic entities.","date":"1997","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/9343323","citation_count":48,"is_preprint":false},{"pmid":"14670959","id":"PMC_14670959","title":"The toxoplasma proteins MIC2 and M2AP form a hexameric complex necessary for intracellular survival.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14670959","citation_count":48,"is_preprint":false},{"pmid":"10202109","id":"PMC_10202109","title":"A role for CD99 in T cell activation.","date":"1999","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10202109","citation_count":48,"is_preprint":false},{"pmid":"34627328","id":"PMC_34627328","title":"CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity.","date":"2021","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34627328","citation_count":46,"is_preprint":false},{"pmid":"10786814","id":"PMC_10786814","title":"Immunoreactivity of MIC2 (CD99) in acute myelogenous leukemia and related diseases.","date":"2000","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/10786814","citation_count":45,"is_preprint":false},{"pmid":"25501132","id":"PMC_25501132","title":"CD99 triggering in Ewing sarcoma delivers a lethal signal through p53 pathway reactivation and cooperates with doxorubicin.","date":"2014","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/25501132","citation_count":44,"is_preprint":false},{"pmid":"22189791","id":"PMC_22189791","title":"Platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31) and CD99 are critical in lymphatic transmigration of human dendritic cells.","date":"2011","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/22189791","citation_count":44,"is_preprint":false},{"pmid":"16314831","id":"PMC_16314831","title":"Suppression of KCMF1 by constitutive high CD99 expression is involved in the migratory ability of Ewing's sarcoma cells.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16314831","citation_count":44,"is_preprint":false},{"pmid":"23644663","id":"PMC_23644663","title":"CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/23644663","citation_count":42,"is_preprint":false},{"pmid":"8504302","id":"PMC_8504302","title":"The genomic organisation of the human pseudoautosomal gene MIC2 and the detection of a related locus.","date":"1993","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8504302","citation_count":42,"is_preprint":false},{"pmid":"18849489","id":"PMC_18849489","title":"Regulation of HLA class I surface expression requires CD99 and p230/golgin-245 interaction.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18849489","citation_count":42,"is_preprint":false},{"pmid":"15003840","id":"PMC_15003840","title":"Multimerization of the Toxoplasma gondii MIC2 integrin-like A-domain is required for binding to heparin and human cells.","date":"2004","source":"Molecular and biochemical parasitology","url":"https://pubmed.ncbi.nlm.nih.gov/15003840","citation_count":42,"is_preprint":false},{"pmid":"18163232","id":"PMC_18163232","title":"The murine CD99-related molecule CD99-like 2 (CD99L2) is an adhesion molecule involved in the inflammatory response.","date":"2007","source":"Cell communication & adhesion","url":"https://pubmed.ncbi.nlm.nih.gov/18163232","citation_count":41,"is_preprint":false},{"pmid":"15837209","id":"PMC_15837209","title":"In ovo administration of CpG oligodeoxynucleotides and the recombinant microneme protein MIC2 protects against Eimeria infections.","date":"2005","source":"Vaccine","url":"https://pubmed.ncbi.nlm.nih.gov/15837209","citation_count":39,"is_preprint":false},{"pmid":"23486730","id":"PMC_23486730","title":"Overexpression of CD99 Increases the Migration and Invasiveness of Human Malignant Glioma Cells.","date":"2012","source":"Genes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23486730","citation_count":39,"is_preprint":false},{"pmid":"11037347","id":"PMC_11037347","title":"CD99 immunoreactivity in gastrointestinal and pulmonary neuroendocrine tumours.","date":"2000","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11037347","citation_count":37,"is_preprint":false},{"pmid":"14623115","id":"PMC_14623115","title":"The CD99 signal enhances Fas-mediated apoptosis in the human leukemic cell line, Jurkat.","date":"2003","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/14623115","citation_count":37,"is_preprint":false},{"pmid":"31209202","id":"PMC_31209202","title":"Exosomes from CD99-deprived Ewing sarcoma cells reverse tumor malignancy by inhibiting cell migration and promoting neural differentiation.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31209202","citation_count":36,"is_preprint":false},{"pmid":"18250143","id":"PMC_18250143","title":"Vaccination against CD99 inhibits atherogenesis in low-density lipoprotein receptor-deficient mice.","date":"2008","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/18250143","citation_count":36,"is_preprint":false},{"pmid":"12172043","id":"PMC_12172043","title":"Immunoreactivity of CD99 in stomach cancer.","date":"2002","source":"Journal of Korean medical science","url":"https://pubmed.ncbi.nlm.nih.gov/12172043","citation_count":34,"is_preprint":false},{"pmid":"34312421","id":"PMC_34312421","title":"Leukocytes with chromosome Y loss have reduced abundance of the cell surface immunoprotein CD99.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/34312421","citation_count":34,"is_preprint":false},{"pmid":"3502698","id":"PMC_3502698","title":"Recombination between the X and Y chromosomes: implications for the relationship between MIC2, XG and YG.","date":"1987","source":"Annals of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/3502698","citation_count":34,"is_preprint":false},{"pmid":"10642936","id":"PMC_10642936","title":"High CD99 expression in memory T and B cells in reactive lymph nodes.","date":"1999","source":"Journal of Korean medical science","url":"https://pubmed.ncbi.nlm.nih.gov/10642936","citation_count":31,"is_preprint":false},{"pmid":"26773145","id":"PMC_26773145","title":"Cutting Edge: CD99 Is a Novel Therapeutic Target for Control of T Cell-Mediated Central Nervous System Autoimmune Disease.","date":"2016","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/26773145","citation_count":30,"is_preprint":false},{"pmid":"36647156","id":"PMC_36647156","title":"EREG is the core onco-immunological biomarker of cuproptosis and mediates the cross-talk between VEGF and CD99 signaling in glioblastoma.","date":"2023","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36647156","citation_count":30,"is_preprint":false},{"pmid":"22020966","id":"PMC_22020966","title":"CD99 triggers upregulation of miR-9-modulated PRDM1/BLIMP1 in Hodgkin/Reed-Sternberg cells and induces redifferentiation.","date":"2011","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22020966","citation_count":30,"is_preprint":false},{"pmid":"18234675","id":"PMC_18234675","title":"Biophysical characterization of O-glycosylated CD99 recognition by paired Ig-like type 2 receptors.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18234675","citation_count":30,"is_preprint":false},{"pmid":"20453109","id":"PMC_20453109","title":"Death induction by CD99 ligation in TEL/AML1-positive acute lymphoblastic leukemia and normal B cell precursors.","date":"2010","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/20453109","citation_count":27,"is_preprint":false},{"pmid":"29382926","id":"PMC_29382926","title":"Clofarabine inhibits Ewing sarcoma growth through a novel molecular mechanism involving direct binding to CD99.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/29382926","citation_count":27,"is_preprint":false},{"pmid":"28003343","id":"PMC_28003343","title":"Ectodomain shedding of CD99 within highly conserved regions is mediated by the metalloprotease meprin β and promotes transendothelial cell migration.","date":"2016","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/28003343","citation_count":27,"is_preprint":false},{"pmid":"31371417","id":"PMC_31371417","title":"Clinical and preclinical characterization of CD99 isoforms in acute myeloid leukemia.","date":"2019","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/31371417","citation_count":26,"is_preprint":false},{"pmid":"31472965","id":"PMC_31472965","title":"Nrf2 induced cisplatin resistance in ovarian cancer by promoting CD99 expression.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/31472965","citation_count":26,"is_preprint":false},{"pmid":"17473187","id":"PMC_17473187","title":"Clinical significance of CD99 down-regulation in gastric adenocarcinoma.","date":"2007","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/17473187","citation_count":26,"is_preprint":false},{"pmid":"22494937","id":"PMC_22494937","title":"Eimeria tenella heat shock protein 70 enhances protection of recombinant microneme protein MIC2 subunit antigen vaccination against E. tenella challenge.","date":"2012","source":"Veterinary parasitology","url":"https://pubmed.ncbi.nlm.nih.gov/22494937","citation_count":25,"is_preprint":false},{"pmid":"9271207","id":"PMC_9271207","title":"The yeast mic2 mutant is defective in the formation of mannosyl-diinositolphosphorylceramide.","date":"1997","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/9271207","citation_count":25,"is_preprint":false},{"pmid":"17576338","id":"PMC_17576338","title":"Differentiating spitzoid melanomas from Spitz nevi through CD99 expression.","date":"2007","source":"Journal of cutaneous pathology","url":"https://pubmed.ncbi.nlm.nih.gov/17576338","citation_count":25,"is_preprint":false},{"pmid":"2907798","id":"PMC_2907798","title":"MIC2: a human pseudoautosomal gene.","date":"1988","source":"Philosophical transactions of the Royal Society of London. Series B, Biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/2907798","citation_count":24,"is_preprint":false},{"pmid":"27753659","id":"PMC_27753659","title":"Expression of TLE-1 and CD99 in Carcinoma: Pitfalls in Diagnosis of Synovial Sarcoma.","date":"2018","source":"Applied immunohistochemistry & molecular morphology : AIMM","url":"https://pubmed.ncbi.nlm.nih.gov/27753659","citation_count":24,"is_preprint":false},{"pmid":"17026517","id":"PMC_17026517","title":"Immunoreactivity of CD99 in invasive malignant melanoma.","date":"2006","source":"Journal of cutaneous pathology","url":"https://pubmed.ncbi.nlm.nih.gov/17026517","citation_count":24,"is_preprint":false},{"pmid":"18552083","id":"PMC_18552083","title":"Olig2 and CD99 are useful negative markers for the diagnosis of brain tumors.","date":"2008","source":"Clinical neuropathology","url":"https://pubmed.ncbi.nlm.nih.gov/18552083","citation_count":24,"is_preprint":false},{"pmid":"19307784","id":"PMC_19307784","title":"Human leukocyte transmigration across Galalpha(1,3)Gal-negative porcine endothelium is regulated by human CD18 and CD99.","date":"2009","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/19307784","citation_count":24,"is_preprint":false},{"pmid":"16084754","id":"PMC_16084754","title":"Toxoplasma gondii: microneme protein MIC2.","date":"2005","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/16084754","citation_count":23,"is_preprint":false},{"pmid":"33147457","id":"PMC_33147457","title":"GDF6-CD99 Signaling Regulates Src and Ewing Sarcoma Growth.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/33147457","citation_count":23,"is_preprint":false},{"pmid":"7641436","id":"PMC_7641436","title":"MIC2 detection in tumors of bone and adjacent soft tissues.","date":"1995","source":"Clinical orthopaedics and related research","url":"https://pubmed.ncbi.nlm.nih.gov/7641436","citation_count":23,"is_preprint":false},{"pmid":"7627931","id":"PMC_7627931","title":"Primary cutaneous neuroendocrine tumors. Diagnostic use of cytogenetic and MIC2 analysis.","date":"1995","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/7627931","citation_count":23,"is_preprint":false},{"pmid":"12216109","id":"PMC_12216109","title":"Functional involvement of src and focal adhesion kinase in a CD99 splice variant-induced motility of human breast cancer cells.","date":"2002","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12216109","citation_count":22,"is_preprint":false},{"pmid":"31001265","id":"PMC_31001265","title":"Targeting Tumor Vascular CD99 Inhibits Tumor Growth.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31001265","citation_count":21,"is_preprint":false},{"pmid":"21267687","id":"PMC_21267687","title":"The evaluation of CD99 immunoreactivity and EWS/FLI1 translocation by fluorescence in situ hybridization in central PNETs and Ewing's sarcoma family of tumors.","date":"2011","source":"Pathology oncology research : POR","url":"https://pubmed.ncbi.nlm.nih.gov/21267687","citation_count":21,"is_preprint":false},{"pmid":"22400079","id":"PMC_22400079","title":"TDT (-), KIT (+), CD34 (+), CD99 (+) precursor T lymphoblastic leukemia/lymphoma.","date":"2012","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/22400079","citation_count":21,"is_preprint":false},{"pmid":"28223280","id":"PMC_28223280","title":"Endothelial CD99 supports arrest of mouse neutrophils in venules and binds to neutrophil PILRs.","date":"2017","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/28223280","citation_count":20,"is_preprint":false},{"pmid":"12526082","id":"PMC_12526082","title":"Characterization and epitope mapping of two monoclonal antibodies against human CD99.","date":"2002","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12526082","citation_count":19,"is_preprint":false},{"pmid":"34383378","id":"PMC_34383378","title":"CD99 and polymeric immunoglobulin receptor peptides deregulation in critical COVID-19: A potential link to molecular pathophysiology?","date":"2021","source":"Proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/34383378","citation_count":19,"is_preprint":false},{"pmid":"27764235","id":"PMC_27764235","title":"Investigating CD99 Expression in Leukemia Propagating Cells in Childhood T Cell Acute Lymphoblastic Leukemia.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27764235","citation_count":18,"is_preprint":false},{"pmid":"23152061","id":"PMC_23152061","title":"CD99 ligation upregulates HSP70 on acute lymphoblastic leukemia cells and concomitantly increases NK cytotoxicity.","date":"2012","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/23152061","citation_count":18,"is_preprint":false},{"pmid":"18382710","id":"PMC_18382710","title":"Immunohistochemical study of CD99 and EMA expression in ependymomas.","date":"2008","source":"Medscape journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18382710","citation_count":17,"is_preprint":false},{"pmid":"25411252","id":"PMC_25411252","title":"Structural basis of Toxoplasma gondii MIC2-associated protein interaction with MIC2.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25411252","citation_count":16,"is_preprint":false},{"pmid":"30514763","id":"PMC_30514763","title":"Protein O-fucosyltransferase 2-mediated O-glycosylation of the adhesin MIC2 is dispensable for Toxoplasma gondii tachyzoite infection.","date":"2018","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30514763","citation_count":16,"is_preprint":false},{"pmid":"23145531","id":"PMC_23145531","title":"CD99 expression in Merkel cell carcinoma: a case series with an unusual paranuclear dot-like staining pattern.","date":"2012","source":"Journal of cutaneous pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23145531","citation_count":16,"is_preprint":false},{"pmid":"25423901","id":"PMC_25423901","title":"Identification of host proteins interacting with the integrin-like A domain of Toxoplasma gondii micronemal protein MIC2 by yeast-two-hybrid screening.","date":"2014","source":"Parasites & vectors","url":"https://pubmed.ncbi.nlm.nih.gov/25423901","citation_count":16,"is_preprint":false},{"pmid":"17725386","id":"PMC_17725386","title":"Production, characterization, and functional analysis of newly established CD99 monoclonal antibodies MT99/1 and MT99/2.","date":"2007","source":"Hybridoma (2005)","url":"https://pubmed.ncbi.nlm.nih.gov/17725386","citation_count":16,"is_preprint":false},{"pmid":"18576850","id":"PMC_18576850","title":"Characterization of monoclonal antibodies that recognize the Eimeria tenella microneme protein MIC2.","date":"2008","source":"The Journal of parasitology","url":"https://pubmed.ncbi.nlm.nih.gov/18576850","citation_count":16,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48270,"output_tokens":7040,"usd":0.125205},"stage2":{"model":"claude-opus-4-6","input_tokens":10762,"output_tokens":3856,"usd":0.225315},"total_usd":0.35052,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1989,\n      \"finding\": \"CD99 (E2/MIC2 gene product) is a 32 kDa transmembrane glycoprotein involved in spontaneous rosette formation (homotypic adhesion) of T cells with erythrocytes, establishing its role in T cell adhesion processes.\",\n      \"method\": \"cDNA cloning, mAb blocking of rosette formation, Northern blotting\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — original molecular identification with functional antibody blocking, replicated by multiple subsequent studies\",\n      \"pmids\": [\"2479542\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"CD99 (E2) engagement by specific mAbs triggers homotypic aggregation exclusively of CD4+CD8+ double-positive thymocytes through a pathway dependent on temperature, energy, Mg2+, and intact cytoskeleton, likely mediated by an uncharacterized integrin.\",\n      \"method\": \"mAb crosslinking, cell aggregation assay, integrin blocking experiments, live cell imaging\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean loss-of-function (blocking antibodies) with specific cellular phenotype, mechanistic follow-up with integrin panels\",\n      \"pmids\": [\"7527813\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"CD99 engagement mediates apoptosis of immature double-positive (CD4+CD8+) thymocytes through a caspase-dependent (CPP32/ICE-type protease) pathway involving early mitochondrial alterations and phosphatidylserine exposure, without DNA fragmentation, independent of the Fas/CD95 pathway.\",\n      \"method\": \"mAb-mediated ligation, morphologic analysis, phosphatidylserine exposure assay, caspase inhibitor studies, Fas pathway blockade\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods, specific inhibitor controls, clear mechanistic separation from Fas pathway\",\n      \"pmids\": [\"9058785\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"CD99 engagement on immature thymocytes accelerates mobilization of TCR and MHC class I/II molecules from cytosolic compartments to the plasma membrane (particularly at cell-cell contact sites), without increasing RNA or protein synthesis, suggesting a role in positive selection.\",\n      \"method\": \"mAb ligation, flow cytometry, confocal microscopy, subcellular fractionation\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct localization experiment tied to functional consequence, multiple methods\",\n      \"pmids\": [\"9670951\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Downregulation of CD99 leads to generation of cells with Hodgkin's/Reed-Sternberg (H-RS) phenotype (multinuclearity, CD15 expression, decreased MHC class I and CD45RB, deregulated cytokine secretion), and forced CD99 expression or constitutively active Rac rescues this phenotype, placing CD99 upstream of a Rac-Rho signaling pathway.\",\n      \"method\": \"Antisense transfection, forced expression, constitutively active Rac expression, immunophenotyping\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis via rescue experiment with constitutively active Rac, replicated in patient samples\",\n      \"pmids\": [\"9834235\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"CD99 crosslinking with anti-CD3 Ab markedly enhances T cell proliferation and induces tyrosine phosphorylation of an ~29 kDa protein, demonstrating that CD99 can deliver costimulatory signals via a specific signal transduction pathway in CD4+ peripheral T cells.\",\n      \"method\": \"mAb crosslinking, proliferation assay, tyrosine phosphorylation immunoblot, CD25/CD69/CD40L expression\",\n      \"journal\": \"Cellular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single lab, consistent functional readout but downstream pathway not fully resolved\",\n      \"pmids\": [\"10202109\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CD99 stimulation upregulates alpha4beta1 integrin-dependent T cell arrest on inflamed vascular endothelium under shear stress via the alpha4beta1-VCAM-1 pathway (not alphaLbeta2-ICAM-1), restricted to memory CD4+ T cells.\",\n      \"method\": \"Flow adhesion assay under shear stress, integrin blocking antibodies, T cell subset analysis\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — specific pathway dissection with integrin blocking, physiological flow conditions\",\n      \"pmids\": [\"11069091\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"EBV latent membrane protein 1 (LMP-1) downregulates CD99 expression at the transcriptional level by negatively regulating the CD99 promoter, contributing to H-RS cell generation in Hodgkin's disease.\",\n      \"method\": \"Stable transfection of LMP-1, CD99 promoter-luciferase reporter assay, Northern/Western blotting\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — promoter reporter assay plus stable transfection with multiple readouts, mechanistically defined\",\n      \"pmids\": [\"10607715\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Engagement of specific CD99 epitopes rapidly induces caspase-independent programmed cell death in transformed T cells (but not normal peripheral T cells), distinct from Fas and TRAIL pathways and independent of CD3, CD4, CD45, and p56lck.\",\n      \"method\": \"mAb ligation, morphological analysis, phosphatidylserine exposure, propidium iodide uptake, pathway inhibition experiments\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — rigorous exclusion of known death pathways with multiple controls, replicated across T cell lines\",\n      \"pmids\": [\"11290771\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The two CD99 isoforms (long form and short form) have distinct functional outcomes: the long form alone promotes CD99-induced cell adhesion, whereas coexpression of both isoforms is required to trigger T cell death. When coexpressed, the two proteins form covalent heterodimers located within glycosphingolipid rafts, and raft localization (cholesterol-dependent) is required for apoptosis induction, which involves sphingomyelin degradation.\",\n      \"method\": \"Isoform transfection in CD99-deficient Jurkat cells, lipid raft fractionation, cholesterol depletion, sphingomyelin assay, cell death assays\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — reconstitution in deficient cells with mechanistic follow-up (raft localization, lipid signaling), multiple orthogonal methods\",\n      \"pmids\": [\"12368226\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CD99 ligation via the YG32 epitope enhances Fas-mediated apoptosis in Jurkat T cells by inducing Fas oligomerization, in a caspase-8-dependent manner (blocked by z-IETD-fmk).\",\n      \"method\": \"Epitope-specific mAb ligation, Fas oligomerization assay, caspase inhibitor studies\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — specific mechanistic finding (Fas oligomerization) with inhibitor confirmation, single lab\",\n      \"pmids\": [\"14623115\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Mouse CD99 mediates homophilic cell aggregation (divalent cation-dependent) when transfected into CHO cells; anti-CD99 antibodies block transendothelial migration (TEM) of lymphocytes in vitro independent of which cell type (T cell or endothelial) is pre-treated, and inhibit recruitment of T cells to inflamed skin in a DTH model in vivo.\",\n      \"method\": \"CHO transfection/aggregation assay, in vitro TEM assay, in vivo DTH model with antibody blockade\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vitro and in vivo validation with mechanistic dissection of which cell type requires CD99\",\n      \"pmids\": [\"15280198\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CD99 knockdown in Ewing sarcoma cells reduces growth and migration; CD99 suppresses KCMF1 (potassium-channel modulatory factor 1) expression, and forced KCMF1 expression recapitulates reduced migration, identifying KCMF1 as a downstream mediator through which CD99 promotes cell migration in EWS.\",\n      \"method\": \"RNAi knockdown, rescue with ectopic KCMF1 expression, migration assays, gene expression analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — epistasis via rescue experiment, multiple EWS cell lines tested\",\n      \"pmids\": [\"16314831\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CD99 regulates HLA class I surface expression by physically associating with HLA class I molecules (via transmembrane domain) in the trans-Golgi network and binding p230/golgin-245 (a TGN trafficking protein); IFN-gamma-induced HLA class I upregulation requires CD99, and p230/golgin-245 overexpression downmodulates surface HLA class I.\",\n      \"method\": \"Co-immunoprecipitation, confocal microscopy, TGN fractionation, p230 overexpression, IFN-gamma stimulation\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP, subcellular fractionation, functional consequence of interaction established\",\n      \"pmids\": [\"18849489\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CD99 is recognized as a sialylated O-glycoprotein ligand for paired Ig-like type 2 receptors (PILRs); PILRalpha binds CD99 with Kd ~2.2 µM and PILRbeta with ~85 µM affinity; both O-glycosylation sites (Thr-45 and Thr-50) act as independent PILRalpha binding sites, while PILRbeta specifically requires Thr-45; binding is enthalpically driven for PILRalpha.\",\n      \"method\": \"Surface plasmon resonance, site-directed mutagenesis, thermodynamic analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with SPR kinetics and mutagenesis, quantitative biophysical characterization\",\n      \"pmids\": [\"18234675\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CD99 knockdown in Ewing sarcoma cells reduces tumorigenicity and bone metastasis, induces neurite outgrowth and neural differentiation markers (beta-III tubulin), and increases ERK1/2 phosphorylation, placing CD99 as an inhibitor of neural differentiation acting through the MAPK pathway.\",\n      \"method\": \"shRNA knockdown, xenograft model, neurite outgrowth assay, ERK1/2 phosphorylation immunoblot, differentiation marker expression\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vitro and in vivo KD with mechanistic pathway (MAPK/ERK) identification, multiple differentiation readouts\",\n      \"pmids\": [\"20197622\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CD99 suppresses osteosarcoma cell migration by: forcing expression of CD99wt recruits N-cadherin and β-catenin to adherens junctions; inhibits ACTR2, ARPC1A, ROCK2, and ezrin expression; maintains c-Src in an inactive conformation, thereby inhibiting ROCK2 signaling and reducing ezrin at the cell membrane.\",\n      \"method\": \"Forced expression, migration assays, co-immunoprecipitation, immunoblotting, actin cytoskeleton analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods, specific molecular pathway (c-Src/ROCK2/ezrin axis) defined\",\n      \"pmids\": [\"23644663\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Overexpression of CD99 in glioma cells enhances migration and invasion; CD99 overexpression decreases Rac activity and increases Rho activity, promoting amoeboid cell morphology, independently of Akt, ERK, or JNK signaling.\",\n      \"method\": \"siRNA knockdown, overexpression, orthotopic mouse model, Rac/Rho activity assays, invasion assays\",\n      \"journal\": \"Genes & cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function and gain-of-function with defined pathway (Rac/Rho) and in vivo validation\",\n      \"pmids\": [\"23486730\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"miR-30a-5p binds the 3'UTR of CD99 and regulates its protein expression post-transcriptionally; EWS-FLI1 suppression decreases CD99 protein but not mRNA, mediated through miR-30a-5p induction; re-expression of miR-30a-5p in Ewing cells decreases proliferation and invasion.\",\n      \"method\": \"miRNA 3'UTR reporter assay, miRNA overexpression, protein/mRNA quantification, proliferation and invasion assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct 3'UTR binding demonstrated, mechanistic link between EWS-FLI1/miR-30a-5p/CD99 established\",\n      \"pmids\": [\"22986530\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Anti-CD99 antibody (dAbd C7) triggers Ewing sarcoma cell death through Mdm2 degradation and p53 reactivation, with induction of p21, Bax, and mitochondrial depolarization; Mdm2 overexpression or p53 silencing reduces CD99-induced death, while nutlin-3 enhances it, requiring an aberrant (EWS-FLI1) genetic context.\",\n      \"method\": \"Anti-CD99 diabody treatment, Mdm2 overexpression, p53 siRNA, nutlin-3 treatment, in vivo xenograft\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis (Mdm2/p53) with rescue/knockdown, in vitro and in vivo\",\n      \"pmids\": [\"25501132\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Endothelial CD99 signals during transendothelial migration (TEM) by forming a complex with the A-kinase anchoring protein ezrin and soluble adenylyl cyclase (sAC) via its lysine-rich juxtamembrane cytoplasmic tail; this activates PKA, which stimulates membrane trafficking from the lateral border recycling compartment (LBRC) to facilitate leukocyte passage; pharmacologic or genetic inhibition of sAC or PKA arrests neutrophils and monocytes partway through endothelial junctions in vitro and in vivo.\",\n      \"method\": \"Co-immunoprecipitation (CD99-ezrin-sAC complex), sAC pharmacologic inhibition, PKA inhibition, genetic knockdown, in vivo inflammation model, LBRC trafficking assay\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — complex identified by co-IP, mechanistic pathway (sAC-PKA-LBRC) validated by pharmacologic and genetic inhibition in vitro and in vivo\",\n      \"pmids\": [\"26101266\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Ectodomain shedding of CD99 is mediated by the metalloprotease meprin β (with cleavage at an acidic region conserved across vertebrates, consistent with meprin β's preference for aspartate residues), followed by intramembrane proteolysis by γ-secretase; meprin β-induced CD99 shedding promotes transendothelial cell migration, and Mep1b-/- mice have significantly increased CD99 protein levels in lung.\",\n      \"method\": \"Biochemical shedding assay, mass spectrometry cleavage site identification, meprin β-/- mouse model, in vitro TEM assay, γ-secretase inhibitor\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — cleavage site identified by MS, genetic KO mouse validation, functional consequence in TEM demonstrated\",\n      \"pmids\": [\"28003343\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Endothelial CD99 (not leukocyte CD99) supports rapid chemokine-induced neutrophil arrest on venular endothelium and acts at the diapedesis step; endothelial CD99 binds heterophilically to paired immunoglobulin-like receptors (PILRs) on neutrophils, promoting shear-resistant attachment; this interaction was confirmed by co-precipitation and biotin-transfer assays.\",\n      \"method\": \"CD99 gene inactivation in mice, intravital video microscopy, co-precipitation, biotin-transfer assay, flow adhesion assay with anti-PILR antibodies\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — KO mouse, intravital microscopy, biochemical interaction confirmation, multiple orthogonal methods\",\n      \"pmids\": [\"28223280\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Anti-CD99 monoclonal antibodies activate hyperstimulation of macropinocytosis in Ewing sarcoma cells leading to caspase-independent, non-apoptotic cell death resembling methuosis (cytoplasmic vacuole accumulation), requiring RAS-Rac1 downstream signaling; this effect is specific to tumor cells and active in xenografts without immune effectors or complement.\",\n      \"method\": \"Anti-CD99 mAb treatment, macropinocytosis assay, vacuole quantification, RAS-Rac1 pathway inhibition, xenograft model\",\n      \"journal\": \"Journal of cell communication and signaling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — defined mechanism (macropinocytosis/RAS-Rac1) with in vivo validation, review synthesis of prior experimental work\",\n      \"pmids\": [\"29305692\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Clofarabine directly binds the extracellular domain of CD99, inhibits CD99 dimerization and its interaction with downstream signaling components; a membrane-impermeable clofarabine analog retains cytotoxicity, indicating a CD99-surface mechanism independent of intracellular DNA metabolism.\",\n      \"method\": \"Small molecule library screen for CD99 binding, CD99 dimerization assay, membrane-impermeable analog, xenograft model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct binding screen, dimerization assay, membrane-impermeable analog as mechanistic control; single lab\",\n      \"pmids\": [\"29382926\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CD99 long isoform transiently induces ERK and SRC phosphorylation followed by a dramatic decrease; it also induces reactive oxygen species, DNA damage, and apoptosis in AML cells, delaying disease progression in murine leukemia models.\",\n      \"method\": \"Isoform-specific transfection, ERK/SRC phosphorylation immunoblot, ROS assay, DNA damage assay, murine leukemia model\",\n      \"journal\": \"Haematologica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — isoform-specific effects with defined signaling pathway, in vitro and in vivo; single lab\",\n      \"pmids\": [\"31371417\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Nrf2 transcriptionally activates CD99 expression (demonstrated by dual-luciferase reporter assay and ChIP), and this CD99 upregulation mediates Nrf2-induced cisplatin resistance in ovarian cancer cells; CD99 knockdown reverses Nrf2-driven resistance.\",\n      \"method\": \"Dual-luciferase reporter assay, ChIP, Nrf2 and CD99 knockdown/overexpression, CCK-8 viability assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — promoter binding confirmed by ChIP and reporter assay, genetic epistasis demonstrated; single lab\",\n      \"pmids\": [\"31472965\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"The GDF6 prodomain (not the BMP domain) is a ligand for the CD99 extracellular domain; binding recruits CSK (C-terminal Src kinase) to the YQKKK motif in the CD99 intracellular domain, inhibiting Src activity and maintaining Ewing sarcoma cell proliferation; GDF6 silencing causes Src hyperactivation and p21-dependent growth arrest.\",\n      \"method\": \"Co-immunoprecipitation (GDF6 prodomain-CD99), domain mapping, CSK recruitment assay, Src activity assay, GDF6 silencing, p21 reporter\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — co-IP identifying ligand-receptor interaction, specific intracellular docking motif (YQKKK) identified, downstream kinase (CSK-Src) mechanism defined\",\n      \"pmids\": [\"33147457\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CD99 upregulation in Hodgkin/Reed-Sternberg cells induces PRDM1/BLIMP1 expression by suppressing miR-9, which directly targets PRDM1; this CD99-miR-9-PRDM1 axis promotes terminal B-cell differentiation and reorganization of actin cytoskeleton in H/RS cells.\",\n      \"method\": \"CD99 overexpression, miR-9 inhibition, PRDM1 reporter, actin cytoskeleton staining, CD30/CD15/CD38/PAX5 expression analysis\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — miR-9 as downstream mediator validated by inhibition experiments, multiple differentiation markers assessed; single lab\",\n      \"pmids\": [\"22020966\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Mosaic loss of chromosome Y (LOY) in leukocytes reduces CD99 protein abundance on the cell surface (across all six leukocyte types studied), directly linking Y chromosome copy number to CD99 surface expression at the single-cell level.\",\n      \"method\": \"CITE-seq (simultaneous single-cell mRNA and protein quantification), comparison of LOY vs. non-LOY cells\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — single-cell multi-omic quantification, specific to CD99 (autosomal CD proteins unaffected), replicated across six leukocyte types\",\n      \"pmids\": [\"34312421\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CD99 (MIC2 gene product) is a heavily O-glycosylated transmembrane glycoprotein with two isoforms (long/short) that acts as a multifunctional signaling hub: it mediates homotypic T cell adhesion via alpha4beta1 integrin activation, promotes leukocyte transendothelial migration by forming a complex with ezrin and soluble adenylyl cyclase to activate PKA and drive LBRC trafficking, undergoes ectodomain shedding by meprin β and intramembrane cleavage by γ-secretase, interacts heterophilically with neutrophil PILRs via O-glycosylated Thr-45/Thr-50 residues, recruits CSK to its cytoplasmic YQKKK motif upon GDF6 prodomain binding to inhibit Src, signals apoptosis through lipid raft-localized covalent heterodimers activating sphingomyelinase, suppresses osteosarcoma migration via c-Src/ROCK2/ezrin inhibition and N-cadherin/β-catenin stabilization, and in Ewing sarcoma prevents neural differentiation through MAPK/ERK modulation while its downregulation is driven by EBV LMP-1 transcriptionally and post-transcriptionally by miR-30a-5p.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CD99 is a heavily O-glycosylated type I transmembrane glycoprotein that functions as a multifaceted regulator of cell adhesion, transendothelial migration, apoptosis, and differentiation across hematopoietic and mesenchymal lineages. In immune cells, CD99 engagement activates α4β1 integrin–dependent T cell adhesion, promotes leukocyte diapedesis through an endothelial ezrin–soluble adenylyl cyclase–PKA signaling axis that drives lateral border recycling compartment trafficking, and interacts heterophilically with neutrophil PILRs via O-glycosylated Thr-45/Thr-50 residues; its ectodomain is shed by meprin β followed by γ-secretase intramembrane cleavage [PMID:11069091, PMID:26101266, PMID:28223280, PMID:18234675, PMID:28003343]. CD99 signals apoptosis in thymocytes and transformed T cells through covalent long/short isoform heterodimers localized in lipid rafts that activate sphingomyelinase, and in Ewing sarcoma the GDF6 prodomain binds CD99's ectodomain to recruit CSK to its cytoplasmic YQKKK motif, inhibiting Src and maintaining proliferation, while CD99 silencing derepresses MAPK/ERK signaling and triggers neural differentiation [PMID:12368226, PMID:33147457, PMID:20197622]. Loss of CD99 expression—driven transcriptionally by EBV LMP-1 or post-transcriptionally by miR-30a-5p—generates Hodgkin/Reed-Sternberg cell features and deregulates Rac-Rho signaling, whereas in osteosarcoma CD99 suppresses migration by inactivating c-Src/ROCK2/ezrin and stabilizing N-cadherin/β-catenin at adherens junctions [PMID:10607715, PMID:22986530, PMID:9834235, PMID:23644663].\",\n  \"teleology\": [\n    {\n      \"year\": 1989,\n      \"claim\": \"Identification of CD99 as the molecular basis of T cell rosette formation established it as a transmembrane glycoprotein with a direct role in homotypic adhesion, answering the long-standing question of the MIC2 gene product's function.\",\n      \"evidence\": \"cDNA cloning plus mAb blocking of rosette formation in human T cells\",\n      \"pmids\": [\"2479542\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of homotypic adhesion (homophilic vs. heterophilic) not resolved\", \"No signaling pathway identified downstream of engagement\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"The discovery that CD99 ligation induces caspase-dependent apoptosis of CD4+CD8+ thymocytes independent of Fas/CD95 revealed CD99 as a death-signaling receptor on immature T cells, reframing it from a pure adhesion molecule to a regulator of thymic selection.\",\n      \"evidence\": \"mAb ligation on thymocytes with caspase inhibitors and Fas pathway blockade\",\n      \"pmids\": [\"9058785\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Proximal signaling intermediates between CD99 and caspase activation unknown\", \"In vivo relevance in thymic selection not demonstrated\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Two key advances defined CD99's roles beyond adhesion: it accelerates TCR/MHC transport to the surface of thymocytes (implicating it in positive selection), and its loss generates Hodgkin/Reed-Sternberg phenotype rescued by constitutively active Rac, placing CD99 upstream of Rac-Rho signaling.\",\n      \"evidence\": \"Confocal microscopy/subcellular fractionation for TCR transport; antisense knockdown with Rac rescue for H-RS phenotype\",\n      \"pmids\": [\"9670951\", \"9834235\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct physical link between CD99 and Rac-GTPase activation not shown\", \"Mechanism of TCR/MHC vesicle mobilization undefined\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Demonstrating that CD99 engagement activates α4β1 integrin–dependent arrest under shear stress on memory CD4+ T cells, and that EBV LMP-1 transcriptionally represses CD99, connected CD99 to physiological leukocyte trafficking and to Hodgkin lymphoma pathogenesis.\",\n      \"evidence\": \"Flow adhesion assay with integrin blocking; LMP-1 stable transfection with CD99 promoter-luciferase reporter\",\n      \"pmids\": [\"11069091\", \"10607715\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling intermediates between CD99 and α4β1 activation not identified\", \"LMP-1 cis-elements on CD99 promoter not mapped\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"The finding that apoptosis requires coexpression of both CD99 isoforms as covalent heterodimers in lipid rafts activating sphingomyelinase resolved how a single gene generates distinct adhesion versus death outcomes through isoform-specific oligomerization and membrane microdomain partitioning.\",\n      \"evidence\": \"Isoform reconstitution in CD99-deficient Jurkat cells, lipid raft fractionation, cholesterol depletion, sphingomyelin assay\",\n      \"pmids\": [\"12368226\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the sphingomyelinase activated is unknown\", \"Structural basis for covalent heterodimer formation undefined\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Blocking experiments in vitro and in vivo showed that CD99 on both leukocytes and endothelium mediates homophilic interaction required for transendothelial migration, establishing CD99 as a gatekeeper of diapedesis distinct from PECAM-1.\",\n      \"evidence\": \"CHO transfection/aggregation, in vitro TEM assay, DTH model with anti-CD99 antibody in mice\",\n      \"pmids\": [\"15280198\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CD99 acts sequentially with or independently of PECAM-1 during TEM not fully resolved\", \"Endothelial signaling downstream of homophilic engagement unknown at this point\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Two studies in 2008 defined new molecular partnerships: CD99 associates with HLA class I via its transmembrane domain and p230/golgin-245 in the TGN to regulate MHC I surface transport, and CD99 serves as a sialylated O-glycoprotein ligand for PILRα/β with defined binding affinities and glycosylation-site specificity.\",\n      \"evidence\": \"Reciprocal co-IP and TGN fractionation for HLA/p230; SPR with site-directed mutagenesis for PILR binding\",\n      \"pmids\": [\"18849489\", \"18234675\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of PILR binding on neutrophil physiology not yet shown\", \"Whether HLA I trafficking role applies beyond lymphocytes not tested\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"CD99 knockdown in Ewing sarcoma induced neural differentiation with increased ERK1/2 phosphorylation and reduced tumorigenicity, establishing CD99 as an oncogene-dependent differentiation brake acting through MAPK suppression in EWS.\",\n      \"evidence\": \"shRNA knockdown in EWS cells, xenograft model, neurite outgrowth, ERK1/2 phosphorylation assay\",\n      \"pmids\": [\"20197622\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which CD99 suppresses ERK signaling not defined\", \"Whether differentiation effect is cell-autonomous or microenvironment-dependent unclear\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Three parallel studies expanded CD99's context-dependent signaling: in osteosarcoma it suppresses migration via c-Src/ROCK2/ezrin inactivation and N-cadherin stabilization; in glioma it promotes invasion via Rho activation; and in Ewing sarcoma miR-30a-5p post-transcriptionally silences CD99 downstream of EWS-FLI1 suppression.\",\n      \"evidence\": \"Forced expression in osteosarcoma with co-IP and actin analysis; overexpression/siRNA in glioma with Rac/Rho assays and orthotopic model; miR-30a-5p 3'UTR reporter assay in EWS\",\n      \"pmids\": [\"23644663\", \"23486730\", \"22986530\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Opposing migratory effects in osteosarcoma vs. glioma/EWS not mechanistically reconciled\", \"miR-30a-5p regulation of CD99 not validated in non-Ewing contexts\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"The identification of endothelial CD99's signaling complex—ezrin/sAC/PKA activating LBRC trafficking—provided the first complete signaling pathway explaining how CD99 homophilic engagement mechanistically drives leukocyte diapedesis.\",\n      \"evidence\": \"Co-IP of CD99-ezrin-sAC, pharmacologic and genetic inhibition of sAC/PKA, LBRC trafficking assay, in vivo peritonitis model\",\n      \"pmids\": [\"26101266\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the same sAC/PKA pathway operates in leukocyte CD99 signaling unknown\", \"Structural basis for ezrin recruitment to CD99 cytoplasmic tail not resolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Discovery that meprin β cleaves CD99's ectodomain at a conserved acidic motif followed by γ-secretase intramembrane proteolysis revealed a regulated proteolytic cascade that controls CD99 surface levels and promotes transendothelial migration.\",\n      \"evidence\": \"Biochemical shedding assay, MS cleavage site mapping, Mep1b−/− mice, γ-secretase inhibitor, TEM assay\",\n      \"pmids\": [\"28003343\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Fate and function of the released intracellular domain after γ-secretase cleavage unknown\", \"Physiological stimuli that activate meprin β–mediated CD99 shedding not identified\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"In vivo gene inactivation and intravital microscopy demonstrated that endothelial CD99 engages neutrophil PILRs heterophilically to support chemokine-induced arrest and diapedesis, unifying the earlier biophysical PILR-binding data with a physiological leukocyte trafficking function.\",\n      \"evidence\": \"CD99 KO mice, intravital video microscopy, co-precipitation and biotin-transfer assay, anti-PILR blocking\",\n      \"pmids\": [\"28223280\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contributions of homophilic CD99-CD99 vs. heterophilic CD99-PILR interactions during TEM not quantified\", \"Whether PILR engagement triggers specific signaling in neutrophils unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identification of the GDF6 prodomain as a CD99 extracellular ligand that recruits CSK to the intracellular YQKKK motif to inhibit Src answered how CD99 restrains growth arrest in Ewing sarcoma and provided the first defined receptor-ligand-effector signaling axis for CD99.\",\n      \"evidence\": \"Co-IP of GDF6 prodomain with CD99, domain mapping, CSK recruitment and Src activity assays, GDF6 silencing with p21 readout\",\n      \"pmids\": [\"33147457\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether GDF6 prodomain-CD99 interaction occurs in non-Ewing tissues unknown\", \"Crystal structure of CD99-GDF6 prodomain complex not available\", \"Whether CSK recruitment to YQKKK motif is direct or scaffold-mediated not resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Major unresolved questions include the structural basis of CD99 homo- and hetero-oligomerization, how opposing pro-migratory (EWS, glioma) versus anti-migratory (osteosarcoma) effects are contextually determined, and whether the meprin β–released intracellular domain has signaling activity.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No crystal or cryo-EM structure of CD99 extracellular domain\", \"No unified model reconciling tissue-specific opposing migratory outcomes\", \"Intracellular domain fragment function after γ-secretase cleavage uncharacterized\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [0, 1, 11]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [2, 9, 20, 27]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [4, 16, 17, 27]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 3, 9, 14, 22, 29]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [13]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [1, 6, 11, 20, 21, 22]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [2, 8, 9, 19]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4, 5, 15, 16, 17, 27]},\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [0, 6, 11, 20]}\n    ],\n    \"complexes\": [\n      \"CD99-ezrin-sAC signaling complex\",\n      \"CD99 long/short isoform heterodimer\"\n    ],\n    \"partners\": [\n      \"ITGA4\",\n      \"EZR\",\n      \"ADCY10\",\n      \"PILRA\",\n      \"PILRB\",\n      \"MEP1B\",\n      \"GDF6\",\n      \"CSK\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}